Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

EDITAS MEDICINE, INC. Comprehensive Income

EDITAS MEDICINE, INC. (EDIT) reported Comprehensive Income of -$18.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05

  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$18.24M.
  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$24.98M.
  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$5.62M.
  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$25.13M.
  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$160.33M.
  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$237.02M.
  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$149.42M.
  • EDITAS MEDICINE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$223.54M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2026-06-30-$18.24M
10-Q · filed 2026-08-05
-$43.22M
10-Q · filed 2026-08-05
-$48.84M
derived: sum of 3 quarters · filed 2026-08-05
-$73.97M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$24.98M
10-Q · filed 2026-05-05
-$30.60M
derived: sum of 2 quarters · filed 2026-05-05
-$55.73M
derived: sum of 3 quarters · filed 2026-05-05
-$109.04M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$5.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$30.75M
derived: sum of 2 quarters · filed 2026-03-09
-$84.06M
derived: sum of 3 quarters · filed 2026-08-05
-$160.33M
10-K · filed 2026-03-09
2025-09-30-$25.13M
10-Q · filed 2025-11-10
-$78.44M
derived: sum of 2 quarters · filed 2026-08-05
-$154.71M
10-Q · filed 2025-11-10
-$200.36M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$53.31M
10-Q · filed 2026-08-05
-$129.58M
10-Q · filed 2026-08-05
-$175.22M
derived: sum of 3 quarters · filed 2026-08-05
-$236.40M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$76.27M
10-Q · filed 2026-05-05
-$121.92M
derived: sum of 2 quarters · filed 2026-05-05
-$183.09M
derived: sum of 3 quarters · filed 2026-05-05
-$250.82M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$45.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$106.83M
derived: sum of 2 quarters · filed 2026-03-09
-$174.55M
derived: sum of 3 quarters · filed 2026-03-09
-$237.02M
10-K · filed 2026-03-09
2024-09-30-$61.18M
10-Q · filed 2025-11-10
-$128.90M
derived: sum of 2 quarters · filed 2025-11-10
-$191.37M
10-Q · filed 2025-11-10
-$208.60M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$67.72M
10-Q · filed 2025-08-12
-$130.20M
10-Q · filed 2025-08-12
-$147.42M
derived: sum of 3 quarters · filed 2025-08-12
-$191.61M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$62.47M
10-Q · filed 2025-05-12
-$79.70M
derived: sum of 2 quarters · filed 2025-05-12
-$123.88M
derived: sum of 3 quarters · filed 2025-05-12
-$164.18M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31-$17.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
-$61.41M
derived: sum of 2 quarters · filed 2025-03-05
-$101.71M
derived: sum of 3 quarters · filed 2025-03-05
-$149.42M
10-K · filed 2025-03-05
2023-09-30-$44.19M
10-Q · filed 2024-11-04
-$84.48M
derived: sum of 2 quarters · filed 2024-11-04
-$132.20M
10-Q · filed 2024-11-04
-$192.24M
derived: sum of 4 quarters · filed 2025-03-05
2023-06-30-$40.30M
10-Q · filed 2024-08-07
-$88.01M
10-Q · filed 2024-08-07
-$148.06M
derived: sum of 3 quarters · filed 2025-03-05
-$204.69M
derived: sum of 4 quarters · filed 2025-03-05
2023-03-31-$47.71M
10-Q · filed 2024-05-08
-$107.76M
derived: sum of 2 quarters · filed 2025-03-05
-$164.39M
derived: sum of 3 quarters · filed 2025-03-05
-$218.72M
derived: sum of 4 quarters · filed 2025-03-05
2022-12-31-$60.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
-$116.68M
derived: sum of 2 quarters · filed 2025-03-05
-$171.01M
derived: sum of 3 quarters · filed 2025-03-05
-$223.54M
10-K · filed 2025-03-05
2022-09-30-$56.63M
10-Q · filed 2023-11-03
-$110.96M
derived: sum of 2 quarters · filed 2023-11-03
-$163.49M
10-Q · filed 2023-11-03
-$205.36M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30-$54.33M
10-Q · filed 2023-08-02
-$106.86M
10-Q · filed 2023-08-02
-$148.73M
derived: sum of 3 quarters · filed 2024-02-28
-$187.80M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31-$52.53M
10-Q · filed 2023-05-05
-$94.40M
derived: sum of 2 quarters · filed 2024-02-28
-$133.47M
derived: sum of 3 quarters · filed 2024-02-28
-$188.72M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31-$41.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
-$80.94M
derived: sum of 2 quarters · filed 2024-02-28
-$136.19M
derived: sum of 3 quarters · filed 2024-02-28
-$192.95M
10-K · filed 2024-02-28
2021-09-30-$39.08M
10-Q · filed 2022-11-02
-$94.33M
derived: sum of 2 quarters · filed 2022-11-02
-$151.08M
10-Q · filed 2022-11-02
-$213.58M
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30-$55.25M
10-Q · filed 2022-08-03
-$112.01M
10-Q · filed 2022-08-03
-$174.51M
derived: sum of 3 quarters · filed 2023-02-22
-$166.92M
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31-$56.76M
10-Q · filed 2022-05-04
-$119.25M
derived: sum of 2 quarters · filed 2023-02-22
-$111.66M
derived: sum of 3 quarters · filed 2023-02-22
-$135.75M
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31-$62.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
-$54.91M
derived: sum of 2 quarters · filed 2023-02-22
-$78.99M
derived: sum of 3 quarters · filed 2023-02-22
-$116.13M
10-K · filed 2023-02-22
2020-09-30$7.59M
10-Q · filed 2021-11-09
-$16.50M
derived: sum of 2 quarters · filed 2021-11-09
-$53.63M
10-Q · filed 2021-11-09
-$91.33M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30-$24.08M
10-Q · filed 2021-08-05
-$61.22M
10-Q · filed 2021-08-05
-$98.92M
derived: sum of 3 quarters · filed 2022-02-24
-$131.87M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31-$37.14M
10-Q · filed 2021-05-06
-$74.84M
derived: sum of 2 quarters · filed 2022-02-24
-$107.79M
derived: sum of 3 quarters · filed 2022-02-24
-$141.56M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31-$37.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
-$70.65M
derived: sum of 2 quarters · filed 2022-02-24
-$104.42M
derived: sum of 3 quarters · filed 2022-02-24
-$133.61M
10-K · filed 2022-02-24
2019-09-30-$32.95M
10-Q · filed 2020-11-06
-$66.72M
derived: sum of 2 quarters · filed 2020-11-06
-$95.91M
10-Q · filed 2020-11-06
-$120.91M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30-$33.77M
10-Q · filed 2020-08-07
-$62.96M
10-Q · filed 2020-08-07
-$87.96M
derived: sum of 3 quarters · filed 2021-02-26
-$103.28M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31-$29.19M
10-Q · filed 2020-05-08
-$54.19M
derived: sum of 2 quarters · filed 2021-02-26
-$69.51M
derived: sum of 3 quarters · filed 2021-02-26
-$108.18M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31-$25.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
-$40.32M
derived: sum of 2 quarters · filed 2021-02-26
-$78.99M
derived: sum of 3 quarters · filed 2021-02-26
-$109.91M
10-K · filed 2021-02-26
2018-09-30-$15.32M
10-Q · filed 2019-11-12
-$53.99M
derived: sum of 2 quarters · filed 2019-11-12
-$84.91M
10-Q · filed 2019-11-12
-$121.15M
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30-$38.67M
10-Q · filed 2019-08-07
-$38.67M
10-Q · filed 2018-08-07
-$69.58M
10-Q · filed 2019-08-07
-$105.83M
derived: sum of 3 quarters · filed 2020-02-26
-$132.38M
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31-$30.91M
10-Q · filed 2019-05-08
-$30.99M
10-Q · filed 2018-05-04
-$67.16M
derived: sum of 2 quarters · filed 2020-02-26
-$93.71M
derived: sum of 3 quarters · filed 2020-02-26
-$120.22M
derived: sum of 4 quarters · filed 2020-02-26
2017-12-31-$36.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
-$62.80M
derived: sum of 2 quarters · filed 2020-02-26
-$89.30M
derived: sum of 3 quarters · filed 2020-02-26
-$120.40M
10-K · filed 2020-02-26
2017-09-30-$26.55M
10-Q · filed 2018-11-08
-$53.06M
derived: sum of 2 quarters · filed 2018-11-08
-$84.16M
10-Q · filed 2018-11-08
-$123.53M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30-$26.51M
10-Q · filed 2018-08-07
-$57.60M
10-Q · filed 2018-08-07
-$96.98M
derived: sum of 3 quarters · filed 2019-03-01
-$118.00M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31-$31.10M
10-Q · filed 2018-05-04
-$70.47M
derived: sum of 2 quarters · filed 2019-03-01
-$91.49M
derived: sum of 3 quarters · filed 2019-03-01
-$110.53M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31-$39.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$60.40M
derived: sum of 2 quarters · filed 2019-03-01
-$79.44M
derived: sum of 3 quarters · filed 2019-03-01
-$97.18M
10-K · filed 2019-03-01
2016-09-30-$21.02M
10-Q · filed 2017-11-08
-$40.06M
derived: sum of 2 quarters · filed 2017-11-08
-$57.81M
10-Q · filed 2017-11-08
2016-06-30-$19.04M
10-Q · filed 2017-08-09
-$36.79M
10-Q · filed 2017-08-09
2015-12-31-$72.90M
10-K · filed 2018-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30